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Abstract
Genetically related Mycobacterium tuberculosis strains with alterations at codon 516 in the rpoB gene were observed
amongst a substantial number of patients with drug resistant tuberculosis in the Eastern Cape Province (ECP) of South
Africa. Mutations at codon 516 are usually associated with lower level rifampicin (RIF) resistance, while susceptibility to
rifabutin (RFB) remains intact. This study was conducted to assess the rationale for using RFB as a substitution for RIF in the
treatment of MDR and XDR tuberculosis outbreaks. Minimum inhibitory concentrations (MICs) of 34 drug resistant clinical
isolates of M tuberculosis were determined by MGIT 960 and correlated with rpoB mutations. RFB MICs ranged from 0.125 to
0.25 mg/ml in the 34 test isolates thereby confirming phenotypic susceptibility as per critical concentration (CC) of 0.5 mg/
ml. The corresponding RIF MICs ranged between 5 and 15 mg/ml, which is well above the CC of 1.0 mg/ml. Molecular-based
drug susceptibility testing provides important pharmacogenetic insight by demonstrating a direct correlation between
defined rpoB mutation and the level of RFB susceptibility. We suggest that isolates with marginally reduced susceptibility as
compared to the epidemiological cut-off for wild-type strains (0.064 mg/ml), but lower than the current CC (#0.5 mg/ml), are
categorised as intermediate. Two breakpoints (0.064 mg/ml and 0.5 mg/ml) are recommended to distinguish between
susceptible, intermediate and RFB resistant strains. This concept may assist clinicians and policy makers to make objective
therapeutic decisions, especially in situations where therapeutic options are limited. The use of RFB in the ECP may improve
therapeutic success and consequently minimise the risk of ongoing transmission of drug resistant M. tuberculosis strains.
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Introduction
Mutations within an 81-bp fragment of the rpoB gene that
encodes the ß subunit of DNA-dependent RNA polymerase are
responsible for RIF resistance in M. tuberculosis [1–4]. This domain
is found between rpoB codons 507 and 533 and is referred to as the
Rifampicin Resistance Determining Region (RRDR). More than
95% of RIF-resistant isolates have been shown to possess
mutations within the RRDR of the rpoB gene [1–7]. Mutations
in the RRDR at codons 531, 526 and 513 are generally associated
with high-level RIF-resistance [2–4]. In contrast, amino acid
substitutions resulting from specific changes at codons 511, 514,
515, 516, 518, 521, 522 and 533 are correlated with lower levels of
RIF-resistance [2,8,9]. Mutations in the rpoB gene that confer
high-level RIF-resistance (MICs, $32 mg/ml) in M. tuberculosis
have been associated with cross-resistance to RFB (MIC,
$4.0 mg/ml) [2,8,9]. Conversely, isolates that exhibit lower levels
of RIF-resistance MICs (#16 mg/ml) were found to remain
phenotypically susceptible to RFB based on a CC of 0.5 mg/ml
[2,8,9]. Single nucleotide polymorphisms (SNPs) outside the
RRDR near the beginning of the rpoB gene have also been
described to be associated with RIF resistance [5]. This region has
recently been suggested for inclusion as an additional target for the
detection of cross-resistance between RIF and RFB [5]. High-level
RIF-resistance is almost always encountered in clinical practice,
while mutants with lower levels of resistance are less frequently
reported [10]. The clinical impact of low-level RIF-resistance in
multidrug-resistant (MDR) tuberculosis (TB) and extensive drug-
resistant (XDR) TB, collectively referred to as M(X)DR-TB, is less
well-studied and understood.
Epidemiological data based on molecular methods demonstrat-
ed that large numbers of M(X)DR patients in the Eastern Cape
Province (ECP) of South Africa are infected with similar M.
tuberculosis isolates of the atypical Beijing genotype [11]. These
isolates had comparable sequence alterations in the inhA promoter,
katG, rpoB, pncA, embB and rrs (500 and 1400 regions) genes which
mediate isoniazid (INH), RIF, pyrazinamide, ethambutol (EMB),
streptomycin and amikacin/kanamycin resistance, respectively
[11]. These similarities suggest genotypic clustering of circulating
strains which are likely responsible for wide-spread transmission of
M(X)DR-TB in the ECP. Of particular interest is the high
proportion (77%) of the atypical Beijing isolates harbouring SNPs
at codon 516 in the rpoB gene [11], which is expected not to
mediate RFB-resistance [2,9,12]. Based on these observations, it
was decided to investigate the possibility of using RFB as
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a substitute for RIF to treat these M(X)DR TB-infected patients.
Hence, our objectives: (i) to correlate the MICs of RIF and RFB in
a subset of M(X)DR M. tuberculosis isolates (ii) to analyse the MIC
data to establish whether cross-resistance occurs between RIF and
its analogue RFB and, (iii) to translate the gained knowledge into
clinical practice for further assessment concerning RFBs potential
to improve clinical outcome.
Materials and Methods
Clinical Isolates
Amongst a collection of 342 M(X)DR M. tuberculosis clinical
isolates obtained from patients resident in the ECP, South Africa,
217 (63%) were previously characterised as members of the
atypical Beijing lineage [11]. The isolates were cultured from
patients with pulmonary TB, but data on the HIV (human
immunodeficiency virus) status and the clinical history of the
patients were not available. Seventy seven percent (168/217) of the
atypical Beijing strains harboured a mutation at codon 516 in the
rpoB gene and 151/168 (90%) of these had an Asp516Val
(GACRGTC) alteration. A convenience sample of 34/168 isolates
(Table 1) with SNPs in the rpoB gene at codon 516 was selected for
this study. The selection was based on genotypic data which reflect
a high degree of homology between the atypical Beijing isolates
[11]. All the isolates had known sequence alterations in the inhA
promoter, katG (315), rpoB (516), pncA (Ins172) and embB (306)
genes [11]. In addition, high confidence drug-resistance conferring
mutations were observed in the rrs (500 and 1400 regions) and gyrA
genes. H37Rv (ATCC 27294) and 27M. tuberculosis clinical isolates
were included for quality control purposes. Two of the isolates
were genotypically and phenotypically resistant and 26 susceptible
to RIF (Table 1).
MIC Determinations
MICs for all selected isolates were determined for RIF and RFB
by quantitative drug susceptibility testing (QDST) in BACTEC
MGIT 960 eXtended individual Susceptibility Testing (TB
eXiST) for EpiCenter TM V5.75A, (BD Bioscience, Erembode-
gem, Belgium) as previously described [13]. The drugs were
purchased from Sigma-Aldrich, South Africa. RIF and RFB were
dissolved in dimethyl sulfoxide and then diluted in sterile distilled
water. Stock solutions of each drug were prepared at concentra-
tions that were at least 84 times higher than the highest test
concentration used. The stock solutions were filter sterilized and
small aliquots were then stored at280uC. The MICs for RIF were
determined at 0.5 mg/ml, 1.0 mg/ml, 10.0 mg/ml, 15.0 mg/ml
and 20.0 mg/ml and for RFB at 0.03 mg/ml, 0.06 mg/ml,
0.125 mg/ml, 0.25 mg/ml, 0.5 mg/ml and 1.0 mg/ml. CCs of
1.0 mg/ml and 0.5 mg/ml were used to determine the susceptibil-
ities of the strains against RIF and RFB, respectively [14]. The
relative resistance (RR) of the isolates against the drugs was
measured by: Mutant MICs/Wild-type MICs.
Results
The MICs for RIF and RFB as determined in this study are
summarised in Table 1. The selected 34 isolates possessed either
an Asp516Tyr (n = 1), Asp516Ser (n = 4) or an Asp516Val (n = 29)
rpoB mutation. The RIF MICs for these isolates were 5 mg/ml
(n = 2) and 10–15 mg/ml (n = 32), which clearly distinguished
them from H37Rv and the 25 wild-type strains which displayed
MICs of #0.5 mg/ml. The level of RIF resistance were thus 5- to
15- fold above the CC, but much lower than those generally
displayed by strains harbouring mutations at codons 526 and 531
(MICs, $50 to $250 mg/ml) [7,10]. However, the corresponding
MICs for RFB ranged between 0.125 and 0.25 mg/ml, which was
a 1/4 to a 1/2 of its CC of 0.5 mg/ml [14]. The MICs for the 26
wild-type strains ranged from #0.03 to 0.06 mg/ml for RFB. Two
mutant control strains with SNPs at codons Ser531Leu and
Gln510Pro in the rpoB gene had MICs of .10 mg/ml and
.1.0 mg/ml for RIF and RFB, respectively. These susceptibility
levels were well within the resistance ranges of the respective
drugs.
Discussion
The 34 clinical isolates were phenotypically susceptible to RFB
as per CC, despite of their resistance to RIF and the presence of
SNPs at codon 516 in the rpoB gene (Table 1). However, a shift in
the RFB MICs, from #0.03–0.06 mg/ml for wild-type strains to
0.125–0.25 mg/ml for the mutant isolates was observed. The
corresponding MIC shift for RIF was from #0.5 mg/ml to 5.0–
15.0 mg/ml. Based on these findings, the relative resistance of the
drugs (Table 1) shows that RFB was less affected by the mutations
at codon 516 in the rpoB gene as compared to RIF [2,8,9]. The
decreased susceptibility to RFB may not predict clinical resistance,
but indicate that mutations at codon 516 in the RRDR are
associated with incomplete cross-resistance between RIF and RFB.
More recently, an epidemiological cut-off (ECOFF) concentration
of 0.064 mg/ml was proposed for RFB based on the Middlebrook
7H10 dilution method [15]. The ECOFF is defined as the highest
concentration within the MIC distribution of wild-type strains (i.e.
isolates lacking resistance mechanisms) [15]. A breakpoint for
RFB, based on clinical evidence has not yet been established.
According to the CC (0.5 mg/ml) endorsed by the World Health
Organization [14], our results suggest that a substantial proportion
M(X)DR TB patients in the ECP may benefit from a treatment
regimen that substitute RIF for RFB. This strategy is feasible only
if the strains that remain susceptible to RFB are readily detectable.
Molecular assays are therefore useful to assist culture-based drug
susceptibility testing (DST) in identifying isolates with specific
mutations that are associated with RIF-resistance, while they
remain susceptible to RFB. The GenoTypeH MTBDplus assay
(Hain LifeScience GmbH, Nehren, Germany) is designed to detect
most of the mutations that confer RIF- and INH- resistance and
has been suggested to be an important tool to define RFB
susceptibility [16]. However, molecular assays with enhanced
discriminating capacity are needed for identifying mutations that
confer low-level or incomplete cross-resistance to analogue drugs.
This information is crucial, particularly for the rifamycins, INH,
Table 1. MICs and relative resistance of rifampicin and
rifabutin in M. tuberculosis.
Genotype rpoB Rifampicin Rifabutin
Mutants (n) MIC mg/ml bRR MIC mg/ml RR
Atypical Beijing D516T (1) 5.0 10 0.125 2
D516S (4) 5.0–15 10–30 0.125–0.25 2–4
D516V (29) 10–15 20–30 0.125–0.25 2–4
Undetermined aWild-type (26) #0.5 – #0.06 –
Typical Beijing S531L (1) .10 .20 .1.0 .16
Atypical Beijing Q510P (1) .10 .20 .1.0 .16
aTwenty-five clinical isolates with unknown genotype plus one H37Rv strain
were included as controls.
bRR indicates relative resistance: Mutant MIC/Wild-type MIC.
doi:10.1371/journal.pone.0059414.t001
MICs of Rifabutin in M(X)DR M. tuberculosis
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the fluoroquinolones and the injectable drugs as the definition of
MDR- and XDR- TB is based on these compounds [17].
Furthermore, mutations outside the RRDR, in the beginning of
the rpoB gene, have also been associated with resistance to both
RIF and RFB, while others confer resistance only to RIF [5].
Molecular assays that exclude this region and only target the
RRDR in the rpoB gene may give a genotypic susceptible result
which does not match the resistance phenotype [5].
Previous studies reported on borderline RIF-resistance, missed
by standard DST [10,18]. The particular isolates possessed rpoB
mutations that were associated with low-level RIF-resistance as
confirmed by their MICs [10,18]. In another study, isolates from
an outbreak of MDR-TB were identified with low-level RIF-
resistance [9]. All the isolates harboured an Asp516Tyr mutation
in the rpoB gene and displayed MICs of 0.5–2 mg/ml for RIF and
0.2–0.5 mg/ml for RFB [9]. These studies suggest that low-level
RIF-resistance can be overcome by the use of higher RIF doses or
alternatively, by replacing RIF with RFB [9,10]. A retrospective
study in South Korea showed an 85.7% (12/14) treatment success
in patients with RFB-susceptible MDR-TB infections who re-
ceived RFB as an additional drug [19]. In our study, the MIC
distribution for RFB was above the ECOFF, but below the
standard CC. Using of the ECOFF as clinical breakpoint for RFB
as recently suggested [15] may be misleading as strains with
decreased susceptibility that remain treatable may be overlooked.
M. tuberculosis strains with moderate decreases in susceptibility to
RFB should rather be classified as intermediate. Clinical isolates in
this category can be distinguished from those that are clearly
susceptible or resistant by introducing a second breakpoint and/or
by the use of a molecular assay. Our results and existing data
[9,10,14,15,18] suggest an intermediate classification that encom-
passes MICs above the ECOFF (0.064 mg/ml), but below or equal
to the current CC (0.5 mg/ml). The peak serum concentration of
RFB at a single dosage of 300 mg ranges from 0.4 mg/ml to
0.6 mg/ml [20]. Increased RFB dosages may not be an option to
increase these levels due to possible toxicity issues. However, the
pharmacokinetics of RFB are in part misleading as its blood levels
do not reflect the concentrations that are attained in infected cells
and tissues where the drug tends to accumulate [20]. Furthermore,
a twofold reduction in the MICs of both RFB and EMB has
previously been indicated owing to synergy between these two
drugs when used together [20].
Our study reinforces the notion that the heterogeneous MIC
levels observed in drug resistant M. tuberculosis strains may have
important therapeutic implications [21–24]. Of particular rele-
vance is the presence of mutations that confer low-level drug-
resistance as it offers possibilities for more effective treatment of
drug resistant TB [21–24]. Knowledge of incomplete cross-
resistance between the rifamycins and the identification of isolates
with intermediate RFB susceptibility should assist clinicians to
make objective therapeutic decisions regarding its potential use in
M(X)DR-TB treatment-regimens. Designing a treatment regimen
for M(X)DR-TB is challenging and the substitution of one or two
drugs in a failing regimen must be done with caution to avoid the
development of further resistance. Relevant clinical studies are
thus imperative to establish appropriate RFB-based regimens that
warrant favourable clinical outcome.
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